Aigen Investment Management, LP Biocryst Pharmaceuticals Inc Transaction History

Aigen Investment Management, LP

$487 Million
Q3 2024

A detailed history of Aigen Investment Management, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Aigen Investment Management, LP holds 28,661 shares of BCRX stock, worth $214,670. This represents 0.04% of its overall portfolio holdings.

Number of Shares

28,661

Previous 16,381 74.96%

Holding current value

$214,670

Previous $101,000 114.85%

% of portfolio

0.04%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$6.41 - $8.69 $78,714 - $106,713	12,280 Added 74.96%	28,661 $217,000
Q2 2024 Aug 09, 2024	SELL	$4.13 - $6.79 $102,093 - $167,848	-24,720 Reduced 60.14%	16,381 $101,000
Q1 2024 May 14, 2024	BUY	$4.89 - $7.65 $139,027 - $217,497	28,431 Added 224.4%	41,101 $208,000
Q4 2023 Feb 09, 2024	SELL	$4.98 - $6.77 $701,203 - $953,243	-140,804 Reduced 91.74%	12,670 $75,000
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $504,451 - $595,417	75,179 Added 96.02%	153,474 $1.09 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $248,973 - $315,151	35,772 Added 84.12%	78,295 $551,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $337,632 - $503,472	42,523 New	42,523 $354,000
Q2 2022 Aug 02, 2022	SELL	$7.89 - $17.88 $88,147 - $199,755	-11,172 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$11.56 - $19.76 $129,148 - $220,758	11,172 New	11,172 $182,000
Q2 2021 Aug 10, 2021	SELL	$9.5 - $17.24 $205,086 - $372,177	-21,588 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$7.37 - $13.61 $159,103 - $293,812	21,588 New	21,588 $220,000
Q3 2020 Nov 06, 2020	SELL	$3.43 - $5.53 $47,965 - $77,331	-13,984 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$1.9 - $5.61 $26,569 - $78,450	13,984 New	13,984 $67,000

Others Institutions Holding BCRX

# of Institutions

280

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.

Account

Aigen Investment Management, LP Biocryst Pharmaceuticals Inc Transaction History